These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 37280463)

  • 41. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
    Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
    Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing.
    Clark TE; Edom N; Larson J; Lindsey LJ
    Drug Saf; 2001; 24(2):87-117. PubMed ID: 11235821
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intravenous brexanolone for postpartum depression: what it is, how well does it work, and will it be used?
    Faden J; Citrome L
    Ther Adv Psychopharmacol; 2020; 10():2045125320968658. PubMed ID: 33224470
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Adverse events with risankizumab in the real world: postmarketing pharmacovigilance assessment of the FDA adverse event reporting system.
    Shu Y; Chen J; Ding Y; Zhang Q
    Front Immunol; 2023; 14():1169735. PubMed ID: 37256136
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy.
    Day JW; Mendell JR; Mercuri E; Finkel RS; Strauss KA; Kleyn A; Tauscher-Wisniewski S; Tukov FF; Reyna SP; Chand DH
    Drug Saf; 2021 Oct; 44(10):1109-1119. PubMed ID: 34383289
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety of alitretinoin for severe refractory chronic hand eczema: Clinical studies and postmarketing surveillance.
    Morris M; Schifano L; Fong R; Graff O
    J Dermatolog Treat; 2016; 27(1):54-8. PubMed ID: 25886084
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety Profile of the Adjuvanted Recombinant Zoster Vaccine in Immunocompromised Populations: An Overview of Six Trials.
    López-Fauqued M; Co-van der Mee M; Bastidas A; Beukelaers P; Dagnew AF; Fernandez Garcia JJ; Schuind A; Tavares-da-Silva F
    Drug Saf; 2021 Jul; 44(7):811-823. PubMed ID: 34115324
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015.
    Arana JE; Harrington T; Cano M; Lewis P; Mba-Jonas A; Rongxia L; Stewart B; Markowitz LE; Shimabukuro TT
    Vaccine; 2018 Mar; 36(13):1781-1788. PubMed ID: 29477308
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Allopregnanolone in Postpartum Depression.
    Pinna G; Almeida FB; Davis JM
    Front Glob Womens Health; 2022; 3():823616. PubMed ID: 35558166
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Adverse events after Fluzone ® Intradermal vaccine reported to the Vaccine Adverse Event Reporting System (VAERS), 2011-2013.
    Moro PL; Harrington T; Shimabukuro T; Cano M; Museru OI; Menschik D; Broder K
    Vaccine; 2013 Oct; 31(43):4984-7. PubMed ID: 23994022
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Risk evaluation and mitigation strategies: impact on patients, health care providers, and health systems.
    Shane R
    Am J Health Syst Pharm; 2009 Dec; 66(24 Suppl 7):S6-S12. PubMed ID: 19966079
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dalfampridine extended release tablets: 1 year of postmarketing safety experience in the US.
    Jara M; Barker G; Henney HR
    Neuropsychiatr Dis Treat; 2013; 9():365-70. PubMed ID: 23662056
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Safety of gadoxetate disodium: Results from the clinical phase II-III development program and postmarketing surveillance.
    Endrikat JS; Dohanish S; Balzer T; Breuer JA
    J Magn Reson Imaging; 2015 Sep; 42(3):634-43. PubMed ID: 25643844
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Brexanolone For Postpartum Depression: A Novel Approach and a Call for Comprehensive Postpartum Care.
    Jarman AF; MacLean JV; Barron RJ; Wightman RS; McGregor AJ
    Clin Ther; 2020 Jan; 42(1):231-235. PubMed ID: 31910998
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of Serious Postmarket Safety Signals Within 2 Years of FDA Approval for New Cancer Drugs.
    Kim J; Nair A; Keegan P; Beaver JA; Kluetz PG; Pazdur R; Chuk M; Blumenthal GM
    Oncologist; 2020 Apr; 25(4):348-354. PubMed ID: 32297444
    [TBL] [Abstract][Full Text] [Related]  

  • 56. FDA drug safety communications: a narrative review and clinical considerations for older adults.
    Marcum ZA; Vande Griend JP; Linnebur SA
    Am J Geriatr Pharmacother; 2012 Aug; 10(4):264-71. PubMed ID: 22683398
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Occurrence of Pulmonary Oil Microembolism After Testosterone Undecanoate Injection: A Postmarketing Safety Analysis.
    Pastuszak AW; Hu Y; Freid JD
    Sex Med; 2020 Jun; 8(2):237-242. PubMed ID: 32184081
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessing adverse drug reaction reports for antidiabetic medications approved by the food and drug administration between 2012 and 2017: a pharmacovigilance study.
    Stottlemyer BA; McDermott MC; Minogue MR; Gray MP; Boyce RD; Kane-Gill SL
    Ther Adv Drug Saf; 2023; 14():20420986231181334. PubMed ID: 37332887
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Using Postmarket Surveillance to Assess Safety-Related Events in a Digital Rehabilitation App (Kaia App): Observational Study.
    Jain D; Norman K; Werner Z; Makovoz B; Baker T; Huber S
    JMIR Hum Factors; 2021 Nov; 8(4):e25453. PubMed ID: 34751664
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors.
    Verden A; Dimbil M; Kyle R; Overstreet B; Hoffman KB
    Drug Saf; 2018 Apr; 41(4):357-361. PubMed ID: 29196988
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.